Abstract
The aim of the study was to assess the correlation between metabolic response measured through positron emission tomography-computed tomography (PET-CT) with 18 F choline ( 18 F FCH) and overall survival (OS) in patients affected by bone lesions from metastatic castration-resistant prostate cancer treated with 223 Ra dichloride. Eleven subjects were subjected to PET-CT with 18 F FCH before and 1 month after 223 Ra treatment. Reduction in total lesion activity (ΔTLA) between pretreatment and post-treatment scan was determined and patients were divided into responders (ΔTLA >50%) and nonresponders (ΔTLA p < 0.05). Reduction in TLA after 223 Ra treatment seems to be correlated with a trend toward a longer survival.